New agents and regimens for diffuse large B cell lymphoma.

Journal Article (Journal Article;Review)

As a widely recognized standard regimen, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is able to cure two-thirds patients with diffuse large B cell lymphoma (DLBCL), and the remaining patients suffer from refractory or relapsed disease due to resistance to R-CHOP and fare poorly. Unsatisfied outcomes for those relapsed/refractory patients prompted efforts to discover new treatment approaches for DLBCL, including chimeric antigen receptor T cells, bispecific T cell engagers, immunomodulatory drugs, immune checkpoint inhibitors, monoclonal antibodies, antibody-drug conjugates, molecular pathway inhibitors, and epigenetic-modifying drugs. Herein, up-to-date data about the most promising treatment approaches for DLBCL are recapitulated, and novel genetic classification systems are introduced to guide individualized treatment for DLBCL.

Full Text

Duke Authors

Cited Authors

  • Wang, L; Li, L-R; Young, KH

Published Date

  • December 14, 2020

Published In

Volume / Issue

  • 13 / 1

Start / End Page

  • 175 -

PubMed ID

  • 33317571

Pubmed Central ID

  • PMC7734862

Electronic International Standard Serial Number (EISSN)

  • 1756-8722

Digital Object Identifier (DOI)

  • 10.1186/s13045-020-01011-z


  • eng

Conference Location

  • England